Importantly, subcutaneous administration of E7 peptide controlled tumor growth less effectively than intratumoral administration, indicating that delivery of antigen into the tumor microenvironment enhances priming of a tumor antigen-specific CD8+ T cell immune response following chemotherapy [34]. The gene discussed is CD8A; the disease is neoplasm.